
Precision Biosciences (DTIL) Stock Forecast & Price Target
Precision Biosciences (DTIL) Analyst Ratings
Bulls say
Precision BioSciences Inc. is experiencing notable progress in its partnered programs, which serve to further validate the clinical potential and versatility of its ARCUS genome editing platform across a variety of disease settings. The company boasts two wholly-owned ARCUS-based programs that are advancing well, supported by encouraging momentum from partner-led clinical validations. Additionally, impressive results have been observed in preclinical studies, with treated mice exhibiting up to 93% of maximum force output and a 66% improvement in resistance to eccentric injury, highlighting the platform's efficacy and potential applications in therapeutic contexts.
Bears say
Precision BioSciences is experiencing a decline in revenue, particularly due to the conclusion of collaborative agreements, including the Prevail/Lilly partnership, which has dampened financial performance and resulted in reduced cash balances. As of March 31, the company’s cash, cash equivalents, and restricted cash amounted to approximately $100 million, down from a prior estimate of $122 million, reflecting the negative impact of decreased revenue from key agreements as it approaches the end of its preclinical work. Additionally, while the company has secured a $2.5 million license agreement with TGTherapeutics related to CAR T therapy, the overall financial outlook remains challenged due to a reliance on partnerships and a slowing revenue stream as the company transitions through its developmental phases.
This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Precision Biosciences (DTIL) Analyst Forecast & Price Prediction
Start investing in Precision Biosciences (DTIL)
Order type
Buy in
Order amount
Est. shares
0 shares